... out of more than 90 vaccines entering HVTN Phase I testing chosen to progress to Phase II clinical trials. Both HIV/AIDS vaccine and treatment markets are huge and GOVX has the potential to be a key player in the two markets. Management will ...
http://www.americanbankingnews.com/2013/05/04/geovax-labs-given-outperform-rating-at-zacks-govx/
http://www.americanbankingnews.com/2013/05/04/geovax-labs-given-outperform-rating-at-zacks-govx/
No comments:
Post a Comment